T 2048/10 (B7-H3 splice variants, antagonist antibodies/BRISTOL-MYERS SQUIBB) of 21.07.2015
- European Case Law Identifier
- ECLI:EP:BA:2015:T204810.20150721
- Date of decision
- 21 July 2015
- Case number
- T 2048/10
- Petition for review of
- -
- Application number
- 01941978.7
- IPC class
- A01K 67/027A61K 38/17C07K 16/28C07K 14/705G01N 33/53C12Q 1/68C12N 15/12A61K 39/395A61K 48/00C12N 5/10
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES AND THEIR USES FOR IMMUNOMODULATION
- Applicant name
- Bristol-Myers Squibb Company
- Opponent name
- MacroGenics, Inc.
CABINET CAMUS LEBKIRI - Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 114(2)European Patent Convention Art 123(2)European Patent Convention Art 54Rules of procedure of the Boards of Appeal Art 12(2)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)
- Keywords
- Main Request - admissibility (yes); added subject-matter (no)
Remittal to first instance for further prosecution (yes) - Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution on the basis of claims 1 to 12 of the Main Request filed at the oral proceedings before the board.